



Cervical screening: invasive cervical cancer audit 2013 to 2016

Appendix B: Data tables

Table 1. Number and proportion of cases of invasive cervical cancer by audit year and age at diagnosis

Age Group	Audit year*									Total
	2007 to 2008	2008 to 2009	2009 to 2010	2010 to 2011	2011 to 2012	2012 to 2013	2013 to 2014	2014 to 2015	2015 to 2016	
<25	41	28	33	28	25	35	22	17	18	247
25 to 29	562	320	412	346	390	386	422	388	376	3602
30 to 39	760	679	743	563	602	590	558	553	475	5523
40 to 49	380	478	525	457	555	447	425	436	377	4080
50 to 64	186	378	409	411	415	416	350	372	312	3249
65+	234	403	406	357	376	388	341	327	259	3091
Total	2163	2286	2528	2162	2363	2262	2118	2093	1817	19792

*Audit year between 1 April and 31 March

Table 2. Number and proportion of invasive cervical cancer cases by audit year and 5-year age group

Audit Year¹	<20*	20 to 24	25 to 29	30 to 34	35 to 39	40 to 44	45 to 49	50 to 55	55 to 59	60 to 64	65 to 69	70 to 74	75 to 79	80+	Total
2007 to 2008	0	41	255	307	318	256	186	135	127	118	95	91	86	75	2090
2008 to 2009	1	27	320	325	354	295	183	131	132	115	92	78	83	150	2286
2009 to 2010	0	33	412	378	365	311	214	150	132	127	93	95	77	141	2,528
2010 to 2011	0	28	346	273	290	259	198	151	131	129	89	69	72	127	2,162
2011 to 2012	1	24	390	297	305	323	232	158	131	126	89	75	88	124	2,363
2012 to 2013	1	34	386	328	262	256	191	150	158	108	113	82	81	112	2,262
2013 to 2014	1	21	422	299	259	226	199	146	119	85	99	61	74	107	2,118
2014 to 2015	1	16	388	285	268	245	191	152	119	101	85	61	76	105	2,093
2015 to 2016	0	18	376	246	229	192	185	121	94	97	71	53	57	78	1,817
Total	5	242	3,295	2,738	2,650	2,363	1,779	1,294	1,143	1,006	826	665	694	1,019	19,719
Percent															
2007 to 2008	0.0	2.0	12.2	14.7	15.2	12.2	8.9	6.5	6.1	5.6	4.5	4.4	4.1	3.6	100
2008 to 2009	0.0	1.2	14.0	14.2	15.5	12.9	8.0	5.7	5.8	5.0	4.0	3.4	3.6	6.6	100
2009 to 2010	0.0	1.3	16.3	15.0	14.4	12.3	8.5	5.9	5.2	5.0	3.7	3.8	3.0	5.6	100
2010 to 2011	0.0	1.3	16.0	12.6	13.4	12.0	9.2	7.0	6.1	6.0	4.1	3.2	3.3	5.9	100
2011 to 2012	0.0	1.0	16.5	12.6	12.9	13.7	9.8	6.7	5.5	5.3	3.8	3.2	3.7	5.2	100
2012 to 2013	0.0	1.5	17.1	14.5	11.6	11.3	8.4	6.6	7.0	4.8	5.0	3.6	3.6	5.0	100
2013 to 2014	0.0	1.0	19.9	14.1	12.2	10.7	9.4	6.9	5.6	4.0	4.7	2.9	3.5	5.1	100
2014 to 2015	0.0	0.8	18.5	13.6	12.8	11.7	9.1	7.3	5.7	4.8	4.1	2.9	3.6	5.0	100
2015 to 2016	0.0	1.0	20.7	13.5	12.6	10.6	10.2	6.7	5.2	5.3	3.9	2.9	3.1	4.3	100
Total	0.0	1.2	16.7	13.9	13.4	12.0	9.0	6.6	5.8	5.1	4.2	3.4	3.5	5.2	100

¹Audit year between 1 April to 31 March

Table 3. Number and proportion of invasive cervical cancer cases in the audit between 1 April 2013 and 31 March 2016 by audit year and age group

Audit Year	<25	25 to 49	50 to 64	65+	Total
2013 to 2014	22	1,405	350	341	2,118
2014 to 2015	17	1,377	372	327	2,093
2015 to 2016	18	1,228	312	259	1,817
Total	57	4,010	1,034	927	6,028
Percent					
2013 to 2014	1.0	66.3	16.5	16.1	100
2014 to 2015	0.8	65.8	17.8	15.6	100
2015 to 2016	1.0	67.6	17.2	14.3	100
Total	0.9	66.5	17.2	15.4	100

Table 4. Number and proportion of invasive cervical cancer cases in the audit between 1 April 2013 and 31 March 2016, by FIGO Stage*

FIGO Stage	Number	Proportion
1A NOS	554	9.2
1A1	1,309	21.7
1A2	108	1.8
1B+ NOS	131	2.2
1B NOS	717	11.9
1B1	950	15.8
1B2	120	2.0
2 NOS	63	1.0
2A	104	1.7
2B	786	13.0
3 NOS	59	1.0
3A	45	0.7
3B	262	4.3
4 NOS	154	2.6
4A	97	1.6
4B	127	2.1
None available	310	5.1
None recorded	132	2.2
Total	6,028	100

*NOS= not otherwise specified (or not further specified)

Table 5. Number of invasive cervical cancer cases in the audit between 1 April 2013 and 31 March 2016 by age group and FIGO stage

Age	1A	1B	2	3	4	1B+(NOS)	None Recorded	Total
<25	12	23	9	5	3	2	3	57
25 to 49	1,745	1,297	450	132	99	67	220	4,010
50 to 64	180	311	215	87	116	29	96	1,034
65+	34	156	279	142	160	33	123	927
Total	1,971	1,787	953	366	378	131	442	6,028

Table 5a. FIGO stage of invasive cervical cancer cases in the audit between 1 April 2013 and 31 March 2016: estimated percentage distribution, by age

Age	IA	IB	II+III	IV	Total
<25	25.4	43.9	25.3	5.4	100
25 to 49	46.8	34.9	15.5	2.7	100
50 to 64	20.6	34.7	32.4	12.3	100
65+	5.3	22.5	51.9	20.3	100
All ages	35.7	33.1	24.1	7.1	100

Table 6. Number of invasive cervical cancer cases in the audit between 1 April 2013 and 31 March 2016, by FIGO stage and year of diagnosis

Audit year	IA	IB	II	III	IV	IB+(NOS)	None Recorded	Total
2007 to 2008	655	629	273	151	93	115	247	2,163
2008 to 2009	685	685	298	149	118	92	259	2,286
2009 to 2010	836	768	305	164	134	100	221	2,528
2010 to 2011	690	615	315	139	118	95	190	2,162
2011 to 2012	798	688	308	141	157	89	182	2,363
2012 to 2013	706	660	378	141	139	61	177	2,262
2013 to 2014	679	650	325	139	150	47	128	2,118
2014 to 2015	704	590	360	117	121	52	149	2,093
2015 to 2016	588	547	268	110	107	32	165	1,817
Total	6341	5832	2830	1251	1137	683	1718	19,792

*Audit year between 1 April and 31 March

Table 6a. FIGO stage of invasive cervical cancer cases: estimated percentage distribution, by year of diagnosis

Audit year	IA	IB	II+III	IV	Total
2007 to 2008	35.9	35.4	23.0	5.7	100
2008 to 2009	35.0	35.6	22.9	6.5	100
2009 to 2010	37.0	35.3	21.3	6.3	100
2010 to 2011	36.1	33.4	23.9	6.6	100
2011 to 2012	37.3	33.2	21.8	7.6	100
2012 to 2013	33.7	32.9	26.0	7.3	100
2013 to 2014	34.6	33.7	23.8	7.8	100
2014 to 2015	36.6	31.6	25.0	6.7	100
2015 to 2016	36.0	34.1	23.2	6.7	100
Total	35.8	34.0	23.4	6.8	100

*Audit year between 1 April and 31 March

Table 7. Number and proportion of invasive cervical cancer cases in the audit between 1 April 2013 and 31 March 2016, by histology

Audit year	Squamous	Adeno-carcinoma	Adeno-Squamous	Undiff-erentiated	Other	None recorded	Total
2007 to 2008	1,529	408	56	11	29	130	2,163
2008 to 2009	1,607	457	69	14	33	106	2,286
2009 to 2010	1,811	504	72	11	30	100	2,528
2010 to 2011	1,579	403	57	4	41	78	2,162
2011 to 2012	1,695	457	64	14	35	98	2,363
2012 to 2013	1,591	467	71	8	31	94	2,262
2013 to 2014	1,523	418	60	5	39	73	2,118
2014 to 2015	1,428	428	55	3	29	150	2,093
2015 to 2016	1,080	336	26	2	31	342	1,817
Total	13843	3878	530	72	298	1171	19792
Percent							
2007 to 2008	70.7	18.9	2.6	0.5	1.3	6.0	100
2008 to 2009	70.3	20.0	3.0	0.6	1.4	4.6	101
2009 to 2010	71.6	19.9	2.8	0.4	1.2	4.0	100
2010 to 2011	73.0	18.6	2.6	0.2	1.9	3.6	100
2011 to 2012	71.7	19.3	2.7	0.6	1.5	4.1	100
2012 to 2013	70.3	20.6	3.1	0.4	1.4	4.2	100
2013 to 2014	71.9	19.7	2.8	0.2	1.8	3.4	100
2014 to 2015	68.2	20.4	2.6	0.1	1.4	7.2	101
2015 to 2016	59.4	18.5	1.4	0.1	1.7	18.8	100
Total	69.9	19.6	2.7	0.4	1.5	5.9	100

*Audit year between 1 April and 31 March

Table 8. Number and proportion of invasive cervical cancer cases in the audit between 1 April 2013 and 31 March 2016, by age at diagnosis and histology

Age	Squamous	Adeno- carcinoma	Adeno- Squamous	Other (incl. undiff)	None recorded	Total
<25	38	7	2	2	8	57
25 to 49	2698	798	86	53	375	4010
50 to 64	672	225	25	28	84	1034
65+	623	152	28	26	98	927
Total	4031	1182	141	109	565	6028
Percent	0.00	0	0	0	0	0
<25	66.7	12.3	3.5	3.5	14.0	100
25 to 29	67.3	19.9	2.1	1.3	9.4	100
50 to 64	65.0	21.8	2.4	2.7	8.1	100
65+	67.2	16.4	3.0	2.8	10.6	101
Total	66.9	19.6	2.3	1.8	9.4	100

Table 9. Number and proportion of invasive cervical cancer cases in the audit between 1 April 2013 and 31 March 2016, by FIGO Stage and histology

Stage	Squamous	Adeno- carcinoma	Adeno- Squamous	Other (incl. undiff)	None recorded	Total
IA	1503	282	16	12	159	1972
IB	1040	518	44	27	159	1788
II&III	920	202	55	29	113	1319
IV	247	53	14	17	47	378
IB+(NOS)	89	25	4	7	6	131
None recorded	232	102	8	17	81	440
Total	4031	1182	141	109	565	6028
Percent	0	0	0	0	0	0
IA	37.3	23.9	11.3	11.0	28.1	32.7
IB	25.8	43.8	31.2	24.8	28.1	29.7
II&III	22.8	17.1	39.0	26.6	20.0	21.9
IV	6.1	4.5	9.9	15.6	8.3	6.3
IB+(NOS)	2.2	2.1	2.8	6.4	1.1	2.2
None recorded	5.8	8.6	5.7	15.6	14.3	7.3
Total	100	100	100	100	100	100

Table 10. Number of invasive cervical cancer cases in the audit between 1 April 2013 and 31 March 2016, by treatment and age group

Treatment	<25	25 to 49	50 to 64	65+	Total
None	1	137	41	85	264
Cone biopsy/ Loop excision	14	1199	68	22	1303
Trachelectomy	5	107	1	0	113
Simple hysterectomy	0	208	67	12	287
Radical hysterectomy	4	499	128	40	671
Radiotherapy ± hysterectomy	0	19	11	14	44
Chemotherapy ± hysterectomy	1	9	5	2	17
Chemotherapy + radiotherapy ± hysterectomy	2	37	15	7	61
Radiotherapy	3	57	36	158	254
Chemotherapy	2	70	44	39	155
Radiotherapy + Chemotherapy	12	508	255	211	986
Palliative care	0	7	21	61	89
Other	0	6	1	3	10
None recorded	13	1147	341	273	1774
Total	57	4010	1034	927	6028

Table 10a. Proportion of invasive cervical cancer cases in the audit between 1 April 2013 and 31 March 2016, by treatment and age group

Treatment	<25	25 to 49	50 to 64	65+	Total
None	1.8	3.4	4.0	9.2	4.4
Cone biopsy/ Loop excision	24.6	29.9	6.6	2.4	21.6
Trachelectomy	8.8	2.7	0.1	0.0	1.9
Simple hysterectomy	0.0	5.2	6.5	1.3	4.8
Radical hysterectomy	7.0	12.4	12.4	4.3	11.1
Radiotherapy ± hysterectomy	0.0	0.5	1.1	1.5	0.7
Chemotherapy ± hysterectomy	1.8	0.2	0.5	0.2	0.3
Chemotherapy + radiotherapy ± hysterectomy	3.5	0.9	1.5	0.8	1.0
Radiotherapy	5.3	1.4	3.5	17.0	4.2
Chemotherapy	3.5	1.7	4.3	4.2	2.6
Radiotherapy + Chemotherapy	21.1	12.7	24.7	22.8	16.4
Palliative care	0.0	0.2	2.0	6.6	1.5
Other	0.0	0.1	0.1	0.3	0.2
None recorded	22.8	28.6	33.0	29.4	29.4
Total	100	100	100	100	100

Table 11. Number and proportion of invasive cervical cancer cases in the audit between 1 April 2013 and 31 March 2016, by age at diagnosis and treatment

Treatment	<50	50 to 64	65 to 79	80+	Total
None(palliative)	145	62	76	70	353
Cone biopsy/ Loop excision	1213	68	16	6	1303
Trachelectomy	112	1	0	0	113
Hysterectomy only (simple or radical)	711	195	41	11	958
Radiotherapy ± hysterectomy	79	47	97	75	298
Chemotherapy ± hysterectomy	82	49	35	6	172
Chemo + radiotherapy ± hysterectomy	559	270	180	38	1047
Not recorded (Other)	1166	342	192	84	1784
Total	4067	1034	637	290	6028
Percent	0	0	0	0	0
None(palliative)	3.6	6.0	11.9	24.1	5.9
Cone biopsy/ Loop excision	29.8	6.6	2.5	2.1	21.6
Trachelectomy	2.8	0.1	0.0	0.0	1.9
Hysterectomy only (simple or radical)	17.5	18.9	6.4	3.8	15.9
Radiotherapy ± hysterectomy	1.9	4.5	15.2	25.9	4.9
Chemotherapy ± hysterectomy	2.0	4.7	5.5	2.1	2.9
Chemo + radiotherapy ± hysterectomy	13.7	26.1	28.3	13.1	17.4
Not recorded (Other)	28.7	33.1	30.1	29.0	29.6
Total	100	100	100	100	100

Table 12. Number of invasive cervical cancer cases in the audit between 1 April 2013 and 31 March 2016, by FIGO Stage and treatment

Treatment	IA	IB	II	III	IV	IB+(NOS)	None recorded	Total
None(palliative)	56	59	38	31	95	4	70	353
Cone biopsy/ Loop excision	1065	188	12	2	2	4	30	1303
Trachelectomy	15	98	0	0	0	0	0	113
Hysterectomy only (simple or radical)	273	619	36	4	2	9	15	958
Radiotherapy ± hysterectomy	6	65	101	59	48	2	17	298
Chemotherapy ± hysterectomy	2	27	39	25	65	3	11	172
Chemo + radiotherapy ± hysterectomy	11	194	542	163	96	12	29	1047
Not recorded (Other)	544	538	185	82	70	97	268	1784
Total	1972	1788	953	366	378	131	440	6028

Table 12a. FIGO stage of invasive cervical cancer cases: estimated percentage distribution in the audit between 1 April 2013 and 31 March 2016, by treatment

Treatment	IA	IB	II+III	IV	Total
None(palliative)	21.1	22.2	24.5	32.2	100
Cone biopsy/ Loop excision	83.8	14.9	1.1	0.2	100
Trachelectomy	13.3	86.7	0.0	0.0	100
Hysterectomy only (simple or radical)	29.2	66.3	4.3	0.2	100
Radiotherapy ± hysterectomy	2.2	23.3	57.2	17.3	100
Chemotherapy ± hysterectomy	1.4	17.6	40.9	40.1	100
Chemo + radiotherapy ± hysterectomy	1.1	19.4	70.0	9.5	100
Not recorded (Other)	37.6	38.5	18.8	5.1	100
Total	35.7	33.1	24.1	7.1	100

Table 13. Cervical screening status of invasive cervical cancer cases and controls aged 25 to 64 in the audit between 1 April 2013 and 31 March 2016, up to 6 months prior to diagnosis (proportions)

Cervical screening status up to 6 months prior to diagnosis	Population Controls		Cases Stage IA		Cases Stage IB+		Cases Stage not recorded	
	n	%	n	%	n	%	n	%
No cytology test (except within 6 months of diagnosis)								
	1,485	15.5	806	41.8	1027	36.6	91	29.0
Last cytology routine and								
Up to date	5,678	59.1	405	21.0	601	21.4	89	28.3
Lapsed	1,581	16.5	402	20.9	755	26.9	85	27.1
Last cytology early repeat								
Up to date	236	2.5	31	1.6	57	2.0	3	1.0
Lapsed	430	4.5	88	4.6	202	7.2	23	7.3
Last cytology suspend								
Up to date	51	0.5	22	1.1	19	0.7	3	1.0
Lapsed	140	1.5	172	8.9	143	5.1	20	6.4
Total	9,601	100	1926	100	2804	100	314	100

We have used the action code provided by the Exeter call and recall service to determine whether the last cytology test lead to a routine recall, early recall or suspend from the recall programme. After a routine recall interval, we consider the screening to be up to date when the diagnosis occurred within 3.5 years (or 5.5 years for older people) from the routine cytology test. After an action code of early repeat, we consider the screening to be up to date when the diagnosis occurred within 1.25 years (or 0.25 years if the test was inadequate) of the early repeat test. When the last test (6 months before diagnosis) resulted in a 'suspend' code recommending referral to colposcopy and was followed by at least one negative test, people were up to date if the diagnosis was made within 1.5 years of the test leading to the suspend code. Those that were suspended more than 6 months before diagnosis and are not followed by any negative tests are lapsed.

Table 14 Cervical screening status of invasive cervical cancer cases and controls up to 6 months prior to diagnosis (numbers and proportions) in the audit between 1 April 2013 and 31 March 2016, by age

Cervical screening status up to 6 months prior to diagnosis	All Cases					Controls				
	20-24	25-49	50-64	65-79	80+	20-24	20-49	50-64	65-79	80+
No cytology test (except within 6 months of diagnosis)	54	1,635	291	221	136	204	1,414	71	106	197
Last cytology routine and Up to date	1	814	281	240	126	5	4,188	1,490	836	316
Lapsed	0	969	272	123	13	0	1,215	366	224	32
Last cytology early repeat and Up to date	0	64	26	4	2	0	222	14	7	2
Lapsed	1	229	84	30	10	0	366	64	28	13
Last cytology suspend*	1	299	80	19	3	2	183	8	7	0
Total	57	4,010	1,034	637	290	211	7,588	2,013	1,208	560
Percent										
No cytology test (except within 6 months of diagnosis)	94.7	40.8	28.1	34.7	46.9	96.7	18.6	3.5	8.8	35.2
Last cytology routine and Up to date	1.8	20.3	27.2	37.7	43.4	2.4	55.2	74.0	69.2	56.4
Lapsed	0.0	24.2	26.3	19.3	4.5	0.0	16.0	18.2	18.5	5.7
Last cytology early repeat and Up to date	0.0	1.6	2.5	0.6	0.7	0.0	2.9	0.7	0.6	0.4
Lapsed	1.8	5.7	8.1	4.7	3.4	0.0	4.8	3.2	2.3	2.3
Last cytology suspend*	1.8	7.5	7.7	3.0	1.0	0.9	2.4	0.4	0.6	0.0
Total	100	100	100	100	100	100	100	100	100	100

* The categories 'last cytology suspend (not followed by any negative)' and 'last cytology suspend (followed by at least one negative)' found in table 14 are combined due to small numbers. Note that screening histories for people over age 65 are based on tests at ages 50 to 64.

Table 15. Number and percentage of population controls (GP plus district controls) screened in the 3 to 5-year interval preceding the date of diagnosis of their matched case, by age

Age	Total	Not screened in previous interval	Screened once in previous interval	Screened twice in previous interval	Screened ≥3 times in previous interval	
20 to 24	426	384	40	1	1	
25 to 29	1947	722	1083	84	58	
30 to 34	1622	524	938	106	54	
35 to 39	1424	427	909	55	33	
40 to 44	1282	395	815	45	27	
45 to 49	1096	354	694	30	18	
50 to 54	812	171	381	224	36	
55 to 59	652	168	452	20	12	
60 to 64	549	149	386	11	3	
65 to 69	479	152	308	8	11	
70 to 74	336	90	177	61	8	
75 to 79	393	107	193	81	12	
80+	560	220	247	77	16	
Total	11578	3863	6623	803	289	
Percent	National Coverage reported in 2015*	Coverage (≥1 test in interval)	%	%	%	%
20 to 24	3.5	9.9†	90.1	9.4	0.2	0.2
25 to 29	63.5	62.9	37.1	55.6	4.3	3.0
30 to 34	70.4	67.7	32.3	57.8	6.5	3.3
35 to 39	73.1	70.0	30.0	63.8	3.9	2.3
40 to 44	75.1	69.2	30.8	63.6	3.5	2.1
45 to 49	75.2	67.7	32.3	63.3	2.7	1.6
50 to 54	80.8	78.9	21.1	46.9	27.6	4.4
55 to 59	74.6	74.2	25.8	69.3	3.1	1.8
60 to 64	72.4	72.9	27.1	70.3	2.0	0.5
65 to 69	-	68.3	31.7	64.3	1.7	2.3
70 to 74	-	73.2	26.8	52.7	18.2	2.4
75 to 79	-	72.8	27.2	49.1	20.6	3.1
80+	-	60.7	39.3	44.1	13.8	2.9
Total			33.4	57.2	6.9	2.5

* Source: NHS Cervical Screening Programme in England in 2015 to 2016. Note: we have used the 3-yearly coverage for people aged 20 to 49 and the 5-yearly coverage for people aged 50 to 64 using table 1a (see reference 12)

† Note: 69% of controls aged 20 to 24 are aged 24, only 5% are aged 20 or 21. Thus this age group reflects the age at which their matched cases were diagnosed and not of the distribution of people aged 20 to 24 nationally. This explains the difference in coverage nationally to that in the audit.

Table 15a. Number and proportion of population controls (GP plus district controls) screened in the 3 to 5-year interval preceding the date of diagnosis of their matched case, by age group

Age group	Total	Not screened in previous interval	Screened once in previous interval	Screened twice in previous interval	Screened ≥ 3 times in previous interval
<25	706	649	43	6	8
25 to 34	11960	4727	6136	609	488
35 to 49	13661	4432	8283	516	430
50 to 64	6928	1797	3942	969	220
65 to 74	2981	884	1577	438	82
75+	3590	1681	1330	501	78
Total	39826	14170	21311	3039	1306
Percent	Coverage (≥ 1 test in interval)				
<25	8.1	91.9	6.1	0.8	1.1
25 to 34	60.5	39.5	51.3	5.1	4.1
35 to 49	67.6	32.4	60.6	3.8	3.1
50 to 64	74.1	25.9	56.9	14.0	3.2
65 to 74	70.3	29.7	52.9	14.7	2.8
75+	53.2	46.8	37.0	14.0	2.2
Total		35.6	53.5	7.6	3.3

Table 16. Time to previous cytology among screened controls ^{1,2}

Age	Time since last screen					No previous cytology within 9.5 years	Total
	<2.75 yrs.	2.75-3.5 yrs.	3.5-4.75 yrs.	4.75-5.5 yrs.	5.5-9.5 yrs.		
25 to 29	6	125	23	3	7	344	508
30 to 34	3	168	45	17	33	65	331
35 to 39	6	138	36	7	25	33	245
40 to 44	3	115	25	9	19	14	185
45 to 49	1	76	16	3	13	9	118
50 to 54	2	46	10	4	4	2	68
55 to 59	1	1	1	32	19	2	56
60 to 64	1	0	0	20	7	4	32
Total	23	669	156	95	127	473	1543
Percent	0	0	0	0	0	0	0
25 to 29	1.2	24.6	4.5	0.6	1.4	67.7	100
30 to 34	0.9	50.8	13.6	5.1	10.0	19.6	100
35 to 39	2.4	56.3	14.7	2.9	10.2	13.5	100
40 to 44	1.6	62.2	13.5	4.9	10.3	7.6	100
45 to 49	0.8	64.4	13.6	2.5	11.0	7.6	100
50 to 54	2.9	67.6	14.7	5.9	5.9	2.9	100
55 to 59	1.8	1.8	1.8	57.1	33.9	3.6	100
60 to 64	3.1	0.0	0.0	62.5	21.9	12.5	100
Total	1.5	43.4	10.1	6.2	8.2	30.7	100

¹ When a case is identified as potentially screen-detected (one in which cytology results are consistent with screen detection) a screen control is then selected (one with a cytology test taken close in calendar time to the test from which the case was screen detected).

² Screened controls from cases in the audit between 1 April 2013 and 31 March 2016.

Table 16a. Time to previous cytology test among potentially screen-detected^{1,2} cases of cervical cancer and their screened controls

Age	Time to previous screen												<5.5 yrs	
	<3.5 yrs		3.5 to 4.75 yrs		4.75 to 5.5 yrs		5.5 to 9.5 yrs		No previous cytology within 9.5yrs		Total			
	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls
28 to 34	212	302	74	68	25	20	42	40	571	490	924	920	311	390
35 to 49	160	339	64	77	20	19	79	57	229	56	551	547	244	435
50 to 64	23	51	7	11	31	56	16	30	71	8	148	156	61	118
Total	395	692	145	156	76	95	137	127	871	554	1623	1623	616	943
Percent														
	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls
28 to 34	22.9	32.8	8.0	7.4	2.7	2.2	4.5	4.3	61.8	53.3	100	100	33.7	42.4
35 to 49	29.0	62.0	11.6	14.1	3.6	3.5	14.3	10.4	41.6	10.2	100	100	44.3	79.5
50 to 64	15.5	32.7	4.7	7.1	20.9	35.9	10.8	19.2	48.0	5.1	100	100	41.2	75.6
Total	24.3	42.6	8.9	9.6	4.7	5.9	8.4	7.8	53.7	34.1	100	100	38.0	58.1

¹A potentially screen-detected case is one in which cytology results are consistent with screen detection; there is no national record of whether the cytology was in response to screening or to symptoms

² Screen-detected cases in the audit between 1 April 2013 and 31 March 2016.

Table 17. Maximum interval* between cytology tests (over the previous 8 years) among cases with FIGO stage 1B+ diagnosed in the audit between 1 April 2013 and 31 March 2016 and their population controls

Age	Maximum Interval between cytology tests											
	<3.5 yrs		3.5 to 4.75 yrs		4.75 to 5.5 yr		5.5 to 7yrs		>7 yrs or no cytology		Total	
	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls
28 to 34	67	343	120	327	80	178	47	150	328	260	642	1258
35 to 49	234	1108	167	509	47	180	70	192	717	378	1235	2367
50 to 64	78	354	75	324	90	388	41	131	475	259	759	1456
Total	379	1805	362	1160	217	746	158	473	1520	897	2636	5081
Percent												
28 to 34	10.4	27.3	18.7	26.0	12.5	14.1	7.3	11.9	51.1	20.7	100	100
35 to 49	18.9	46.8	13.5	21.5	3.8	7.6	5.7	8.1	58.1	16.0	100	100
50 to 64	10.3	24.3	9.9	22.3	11.9	26.6	5.4	9.0	62.6	17.8	100	100
Total	14.4	35.5	13.7	22.8	8.2	14.7	6.0	9.3	57.7	17.7	100	100

* This analysis shows the longest period between tests in the eight years preceding the date of diagnosis of the case. People under age 28 are not included in this analysis because (even allowing for screening from age 20) they would not have been eligible for screening for the whole of the previous 8 years.

Table 18. Number and percentage of invasive cervical cancer cases in the audit between 1 April 2013 and 31 March 2016 with colposcopic appointment recorded, by age group

Age group	Number of cases	Cases with a recorded colposcopy		Cases with a colposcopy review record		Cases with an action code "suspend"		Cases with a "suspend" code >4 months before diagnosis		Cases with "Suspend" >4 months before diagnosis + colposcopy		Cases with "Suspend" >4 months before diagnosis + colposcopy (excluding colposcopy within 2 months of diagnosis)	
		n	%	n	%	n	%	n	%	n	%	n	%
<25	57	27	47.4	0	0.0	19	33.3	1	1.8	1	100	0	0.0
25 to 34	2016	1302	64.6	67	48.6	1601	79.4	214	10.6	138	64.5	108	50.5
35 to 49	1994	1142	57.3	61	26.9	1378	69.1	373	18.7	227	60.9	136	36.5
50 to 64	1034	418	40.4	27	26.7	541	52.3	213	20.6	101	47.4	61	28.6
65 to 74	430	78	18.1	0	0.0	86	20.0	55	12.8	11	20.0	7	12.7
75+	497	57	11.5	0	0.0	49	9.9	38	7.6	8	21.1	3	7.9
Total	6028	3024	50.2	155	5.1	3674	60.9	894	14.8	486	54.4	315	35.2

Table 19. Original cytology result by review result from cases diagnosed in the audit between 1 April 2009 and 31 March 2011 *

Original result	Review Result																	
	Negative		Inadequate		Borderline		Low-grade (mild)		High-grade (Moderate)		High-grade (severe)		?Invasive		?Glandular		Total	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Negative	2,800	51.1	506	9.2	997	18.2	135	2.5	181	3.3	572	10.4	29	0.5	260	4.7	5,480	100
Inadequate	58	8.2	417	59.1	93	13.2	15	2.1	12	1.7	72	10.2	11	1.6	27	3.8	705	100
Borderline	22	2.3	10	1.0	424	43.4	69	7.1	64	6.6	234	24.0	20	2.0	134	13.7	977	100
Low-grade (mild)	4	1.1	1	0.3	35	9.5	152	41.3	78	21.2	88	23.9	5	1.4	5	1.4	368	100
High-grade (moderate)	1	0.2	0	0.0	6	1.5	4	1.0	138	33.9	229	56.3	19	4.7	10	2.5	407	100
High-grade (severe)	9	0.4	3	0.1	5	0.2	0	0.0	9	0.4	1,788	85.1	204	9.7	84	4.0	2,102	100
?Invasive	1	0.1	0	0.0	0	0.0	0	0.0	1	0.1	41	6.1	621	91.9	12	1.8	676	100
?Glandular	2	0.4	0	0.0	3	0.6	0	0.0	0	0.0	30	5.7	13	2.5	479	90.9	527	100
Total	2,897	25.8	937	8.3	1,563	13.9	375	3.3	483	4.3	3,054	27.2	922	8.2	1,011	9.0	11,242	100

* This is an updated version of Table 1 in Castanon et al , Cytopathology, 2012 23(1)